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Abstract
Objectives The aim of this study was to determine if there was
an association between being discharged on antipsychotic
polypharmacy (APP) and risk of readmission into secondary
mental health care.
Methods Using data from the South London and Maudsley
(SLAM) case register, service users with seriousmental illness
(SMI), discharged between 1st January 2007 and 31th
December 2014, were followed up for 6 months. Patients were
classified as receiving either monotherapy or polypharmacy at
index discharge. Multivariable Cox regression models were
constructed, adjusting for sociodemographic, socioeconomic,
clinical and service use factors.
Results We identified 5523 adults who had been admitted at
least once to SLAM, of whom 1355 (24.5%) were readmitted
into secondary mental health care. In total, 15% (n = 826) of
patients were discharged on APP and 85% (n = 4697) on
monotherapy. Of these, 30.9% (n = 255) and 23.4%
(n = 1100) were readmitted respectively. Being discharged
on APP was associated with a significantly increased risk of
readmission, in comparison to patients discharged on mono-
therapy (HR = 1.4, 1.2–1.7, p < 0.001). This association was
maintained in the fully adjusted model and following several
sensitivity analyses. We further established that patients re-
ceiving clozapine APP (n = 200) were at a significantly
increased risk for readmission in comparison to patients on
clozapine monotherapy (HR = 1.8, 1.2–2.6, p = 0.008).
Conclusions Our results suggest that patients discharged on
APP are more likely to be readmitted into hospital within
6 months in comparison to those discharged on monotherapy.
This needs to be considered in treatment decisions and the
reasons for the association clarified.
Keywords Co-prescribing . Polypharmacy .Antipsychotics .
Rehospitalisation . Readmission
Introduction
An additional regular antipsychotic is frequently added to
treatment [as opposed to pro re nata (PRN)] in inpatient set-
tings to manage residual clinical symptoms following mono-
therapy (Centorrino et al. 2008; Grech and Taylor 2012).
However, antipsychotic polypharmacy (APP) has not been
found to be associated with more clinical improvement from
the time of admission, to the point of discharge, in comparison
to monotherapy (Centorrino et al. 2005; Centorrino et al.
2004; Biancosino et al. 2005), and little is currently known
about APP, once patients return to the community.
Hospital readmission rates are high amongst individuals
with serious mental illness (SMI) (Schennach et al. 2012),
with the risk for rehospitalisation peaking in the first months
after discharge (Bodén et al. 2011). Factors that have been
associated with an increased risk for readmission are shorter
hospital stays (Boaz et al. 2013), medication non-adherence
(Haddad et al. 2014) and comorbid substance use (Boaz et al.
2013).
Research examining predictors of APP has indicated that
patients with higher inpatient and outpatient contact (Kadra
et al. 2016; Ortiz et al. 2016; Centorrino et al. 2004;
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Kreyenbuhl et al. 2007; Connolly and Taylor 2014) and great-
er illness severity (Kadra et al. 2016; Correll and Gallego
2012) are at particular risk of receiving APP prescription.
However, research examining how patients on APP fare post
discharge has been sparse (Correll et al. 2009) and contradic-
tory. For example, evidence has been mainly derived from
medical health insurance records, with findings indicating that
the choice between APP or monotherapy has no effect on the
risk for readmission (Boaz et al. 2013); and that APP is asso-
ciated with lower hospital readmission in comparison to
monotherapy (Katona et al. 2014). There has been sparse ev-
idence to suggest that clozapine is associated with reduced
rehospitalisation (Nielsen et al. 2012; Gee et al. 2016;
Tiihonen et al. 2017), and clozapine augmentation is currently
the only APP regime that has some empirical support
(Freudenreich and Goff 2002; Taylor et al. 2011), hence its
acceptance as a third-line treatment for SMI (NCCMH 2010).
However, it is unclear whether people receiving clozapine
polypharmacy differ in the risk of readmission. Therefore,
the aim of this study was to determine if there was an associ-
ation between being discharged on APP and risk of readmis-
sion, once patients return to the community, using a large
cohort of de-identified electronic health records. Furthermore,
we set out to investigate if the inclusion of clozapine in APP
had an impact on this risk.
Methods
We carried out an observational cohort study using
anonymised data from South London and Maudsley
(SLAM) NHS Foundation Trust electronic health records
(EHRs), collected retrospectively for the time period between
1st January 2007 and 31st December 2014. SLAM is one of
the largest providers of secondary health care in Europe, serv-
ing four London boroughs (Lambeth, Southwark, Lewisham
and Croydon) and a catchment population of approximately
1.36 million (Stewart et al. 2009; Perera et al. 2016). The
Clinical Record Interactive Search (CRIS) system was devel-
oped in 2008 to allow researchers to search and retrieve
anonymised SLAM EHRs within a robust governance frame-
work. Currently, over 280,000 cases are represented. CRIS
was approved by the Oxfordshire Research Ethics
Committee C (reference 08/H606/71+5) in 2008.
Selection criteria and primary outcome
We identified all adults who had received a SMI diagnosis
such as schizophrenia (ICD-10 code: F20.x), schizoaffective
disorder (F25.x) or bipolar disorder (F31.x) between 1st
January 2007 and 31st December 2014. A decision to include
all three of the above diagnoses was made based on discus-
sions with clinicians within the service and previous published
literature. More specifically, clinical symptoms are believed to
lie on a continuum between these diagnoses and it is not un-
common that a diagnosis is changed over the course of the
patient’s illness (Esterberg and Compton 2009). Furthermore,
previous research (Grech and Taylor 2012) has indicated that a
proportion of patients prescribed long-term antipsychotic
polypharmacy have a bipolar affective disorder diagnosis.
We further identified all patients with at least one inpatient
admission during the observation period and who were resi-
dents in the boroughs of SLAM. Patients residing outside the
local catchment area can be referred to SLAM services for
specialist treatment, due to particularly severe or treatment-
resistant symptoms. However, these patients return to their
borough of residence following discharge, and therefore
follow-up for readmission is not possible for this group.
Therefore, this group was excluded. For patients with multiple
admissions, we selected admissions that were followed by a
discharge on clozapine either as a single antipsychotic or as
part of polypharmacy; otherwise, the first recorded admission
was used. This was based on previous evidence suggesting
that clozapine is often under-prescribed in relation to other
antipsychotics and to polypharmacy (Lochmann van
Bennekom et al. 2013), so we sought to identify asmany cases
as we could to increase statistical power sufficient to carry out
an analysis for this group.We followed up all patients from the
point of their index inpatient discharge for a 6-month period to
establish whether or not they were readmitted into secondary
mental health care. Previous research indicates that the risk for
readmission is highest in the 30 days post inpatient discharge
(Boaz et al. 2013), and we reasoned that a 6-month window
would thus capture most readmissions. Readmissions data
were derived from structured fields in CRIS. Follow-up
stopped at the first hospital readmission, date of death, or
31st December 2014, whichever occurred first. Date of death
within the observation windowwas traced for the entire cohort
through routine nationwide mortality tracing linked to the
electronic health record and carried out on a monthly basis
(Perera et al. 2016).
Data extraction
We extracted clinical information in the EHR through CRIS
from structured and unstructured fields (free-text fields such
as clinician–patient encounters and correspondence between
health care professionals). For antipsychotic prescribing, we
also used information available from SLAM pharmacy re-
cords. We examined all antipsychotic drugs listed in the
British National Formulary (BNF) 65. Antipsychotic medica-
tion data in free text was also extracted using a natural lan-
guage processing (NLP) information extraction application
developed using General Architecture for Text Engineering
(GATE) software (Cunningham et al. 2013), a suite of tools
that facilitates the use and development of NLP applications
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and features, and which has been used to derive a large vol-
ume of meta-data in CRIS for previous and current research
(Perera et al. 2016; Kadra et al. 2015). NLP applications take
into account the linguistic context when extracting data from
free text, therefore offering a more sophisticated approach of
extracting information than basic key word searches.
Exposures of interest and other covariates
We examined individual EHRs to ascertain whether patients
were discharged on a single antipsychotic (i.e. monotherapy)
or two or more antipsychotics (i.e. APP). Antipsychotic regi-
men was determined by a patient being prescribed the same
antipsychotic/s during their inpatient stay and in the 6 weeks
following their discharge. In addition, we extracted a number
of sociodemographic, socioeconomic, clinical and service use
features.
Age, gender, ethnicity and relationship status were derived
from structured fields in CRIS. Age was calculated at index
discharge. A likelihood ratio test indicated that it was appro-
priate to use age as a continuous variable in the analysis.
Seventeen ethnic groups were collapsed into six categories
(BBritish^, BOther White^, BAsian^, BCaribbean^, BAfrican^
and BOther^) due to small numbers in some cells. Relationship
status was defined as Brelationship^ (cohabitating, married or
civil partnership) and Bno relationship^ (single, divorced, sepa-
rated, widowed, unknown). We used an area-level index of
multiple deprivation to estimate socioeconomic status based
on seven domains of deprivation ascertained from 2007 UK
Census estimates (employment, income, education, health,
barriers to housing and services, crime and living environ-
ment), which are weighted and combined into an overall score
applied to a given geographic area (DCLG 2011). In this case,
multiple deprivation indices were applied to lower super out-
put areas (LSOAs), each containing on average 1500 residents
(DCLG 2011). LSOAs were categorised in tertiles in the
analysis.
Clinical symptoms were evaluated through Health of the
Nation Outcome Scales (HoNOSs) completed in routine clin-
ical practice, prioritising those completed on or before the
index discharge date. In cases where a HoNOS at or prior to
discharge was not available, we took the closest score avail-
able after the discharge date. HoNOS is a clinical outcome
instrument in wide routine use, composed of 12 items de-
signed to measure behaviour, impairment, symptoms and so-
cial functioning (Wing et al. 1998). Items are scored on a scale
of 0 (no problem) to 4 (severe to very severe problem). Due to
small cell sizes, subscale scores were collapsed into three cat-
egories: 0 Bnot a problem^; 1 Bminor problem requiring no
action^; 2–4 Bsignificant problem^. We further ascertained
whether or not the patient had received a mental illness diag-
nosis due to alcohol (ICD 10: F10) or opioid use (ICD 10:
F11) prior to the index discharge. This information was
extracted from structured and free-text fields. We extracted
two measures of prior service use: (1) the number of days
spent as an inpatient in the 6 months prior to the index dis-
charge date; and (2) the proportion of face-to-face contact
received as an outpatient in the 6 months prior to the index
discharge (multiple events on a single day were counted as
1 day of clinical contact, whilst clinical contact with outpatient
services during an inpatient admission was not counted). Both
variables were categorised in tertiles. For the purpose of a
sensitivity analysis, we tried to establish medication non-ad-
herence, by ascertaining whether patients had ever been pre-
viously on a community treatment order (CTO) [CTO refers to
a conditional discharge from inpatient admission, commonly
implemented for a period of 6 months to improve adherence to
medication and promote regular contact with services (DoH
2007)] and antipsychotic long-acting injectable (LAI) pre-
scription. This information was derived from structured and
free-text fields and categorised as a binary variable, 0 (no
previous history of CTO and LAI use) and 1 (previous history
of both CTO and LAI use).
Statistical analysis
STATA 13was used to conduct all statistical analyses. Sample
characteristics were summarised by percentage of readmission
for the total cohort and by antipsychotic group. Kaplan–Meier
curves with a log-rank test were used to compare those who
were prescribed APP and monotherapy in relation to readmis-
sion. Following checks of proportional hazard assumptions,
Cox regression procedures were used to examine the associa-
tions between APP and risk of readmission.
Possible confounders were decided on a priori, based on
their plausibility as potential confounders and evidence from
previous literature. Age, gender, ethnicity, relationship status,
deprivation status, clinical symptoms (HoNOSs), comorbid
diagnoses and service use in the 6 months prior to the index
discharge date were included as covariates in the multivariable
analysis. We further conducted several sensitivity analyses to
test whether any possible associations between APP and hos-
pital readmissions were maintained after removing factors that
may have had an effect: (1) we excluded patients with prior
history of CTO and LAI use. The above are potential markers
of non-adherence and therefore important to account for when
considering medication use. (2) We restricted the analysis to
all patients with a diagnosis of schizophrenia (ICD 10: F20) in
order to test if the association was maintained for this group.
(3) We excluded patients from the borough of Lewisham as
they did not have SLAM pharmacy data (however, they did
have medication data from structured and free-text fields in
PJS). (4) We excluded patients with HoNOS score obtained
after the index discharge. (5) We restricted the analysis to
patients who had not been prescribed clozapine. (6) To reduce
the effect of confounding by indication, we used a standard
Psychopharmacology
propensity score method, where the propensity score was the
probability of being placed on polypharmacy at index dis-
charge where all the potential confounders described in
Table 1 were included in the model. The propensity scores
were then used as a covariate in place of all of the aforemen-
tioned confounders (i.e. sociodemographic, socioeconomic,
clinical and service use) in the Cox model. Propensity score
was further used to identify patients who were at risk of being
prescribed monotherapy and polypharmacy at discharge. We
then constructed a fully adjusted Cox model and restricted the
analysis to patients with this restricted range of propensity
scores. Finally, we carried out a fully adjusted Cox model,
where patients on clozapine APP and non-clozapine
polypharmacy were compared to patients on clozapine mono-
therapy on their risk of hospital readmission. In this latter
analysis, clozapine monotherapy was considered to be clini-
cally the most meaningful reference group. Clozapine pre-
scribing often involves a period of clinical discussion, as well
as physical and blood checks. Therefore, patients who are
initiated on clozapine could be somewhat different to patients
that have not been initiated on clozapine. Therefore, restricting
this latter analysis to patients that have been prescribed cloza-
pine also reduces confounding by indication.
Results
In total, 5523 individuals met the inclusion criteria for the
study. Table 1 describes the characteristics of the total cohort
and by antipsychotic regimen. Antipsychotic monotherapy
and polypharmacy were very similar in their sociodemograph-
ic and socioeconomic composition. However, there was a
higher proportion of British patients in the monotherapy
group, whereas the polypharmacy group had a higher propor-
tion of patients from black African and black Caribbean ethnic
backgrounds. Furthermore, patients on antipsychotic mono-
therapy were more likely to have been diagnosed with bipolar
affective disorder (ICD 10: F31), whereas patients prescribed
APP were more likely to receive schizophrenia diagnosis.
Patients discharged on APP were also more likely to have
significant problems with hallucinations and/or delusions,
and had more contact with services in the previous 6 months
(both inpatient and outpatient).
Table 2 summarises readmission across the antipsychotic
regimens. Twenty-five per cent (n = 1355) of the sample were
readmitted within 6 months post discharge. In total, 15%
(n = 826) of patients were discharged on APP and 85%
(n = 4697) patients were discharged on monotherapy. Of
these, 30.9% (n = 255) and 23.4% (n = 1100) were readmitted
respectively.
Figure 1 presents the Kaplan–Meier curves comparing re-
admission over time for patients discharged on either antipsy-
chotic monotherapy or polypharmacy. Those prescribed
monotherapy displayed significantly less readmission
(p < 0.001) over time.
Table 3 summarises Cox proportional hazards models for
the association between being discharged on APP and second-
ary mental health care readmission. In summary, APP was
associated with a significantly increased risk for hospital re-
admission; this association was sustained after adjusting for a
number of sociodemographic, socioeconomic, clinical and
service use factors, and changed little after alternative adjust-
ment for propensity scores. We further conducted a number of
sensitivity analyses, also described in Table 3, which again
had little impact on the main outcome.
Clozapine polypharmacy constituted 4% of the sample
(n = 200), whereas non-clozapine polypharmacy was 11.3%
(n = 626). A fully adjusted Cox proportional hazards model
indicated that clozapine APPwas associated with significantly
increased risk for readmission in comparison to clozapine
monotherapy (HR = 1.8, 1.2–2.6, p = 0.008) (Table 4).
However, when we compared the risk for readmission be-
tween clozapine monotherapy and non-clozapine APP, we
found no significant difference between the two regimens
(HR = 1.4, 0.9–1.9, p = 0.063).
Discussion
This study examined the association between being discharged
on APP from inpatient settings and subsequent mental health
care readmissions, in a retrospective analysis of a large cohort
of patients, taking into account a wide range of other covariates.
In summary, we found that patients discharged on APP (wheth-
er including clozapine or not) were at an increased risk of
rehospitalisation. This association remained statistically signif-
icant and relatively unaltered in strength after multiple adjust-
ments, sensitivity analyses and the use of propensity score
methods to address confounding by indication. The results fur-
ther indicated that patients discharged on clozapine polyphar-
macy had an even greater risk for readmission when compared
to patients on clozapine monotherapy.
Previous research on APP as a predictor of readmission has
been sparse and inconclusive. Our findings were consistent
with evidence from clinical record studies (Kreyenbuhl et al.
2007), indicating that patients prescribed APPwere more like-
ly to be admitted to secondary mental health care inpatient
settings. For example, Kreyenbuhl et al. (2007) found that
patients who had an additional antipsychotic prescribed, as
opposed to being switched to a different antipsychotic, were
three times more likely to be hospitalised. However, our find-
ings were not in agreement with previous research investigat-
ing medical insurance records and rehospitalisation amongst
patients prescribed long-term APP (Boaz et al. 2013; Katona
et al. 2014). For example, Boaz and colleagues (Boaz et al.
2013) found that polypharmacy at discharge was not
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Table 1 Sample characteristics by antipsychotic regimen prescribed at index dischargea (N = 5523)
Variables Total sample n Antipsychotic
monotherapy n (%)
Antipsychotic
polypharmacy n (%)
Sociodemographic and socioeconomic factors
Age
Mean (SD) 41.3 (14.5) 41.3 (14.7) 41.4 (13.1)
Gender
Female 2573 2185 (46.5) 388 (47.0)
Male 2950 2512 (53.5) 438 (53.0)
Ethnicity groupa
British 1662 1447 (30.8) 215 (26.0)
Other White 453 383 (8.2) 70 (8.5)
Asian 334 285 (6.1) 49 (5.9)
Caribbean 730 596 (12.7) 134 (16.2)
African 1926 1623 (34.6) 303 (36.7)
Other 418 363 (7.7) 55 (6.7)
Relationship status
No relationship 4806 4083 (86.9) 723 (87.5)
Relationship 717 614 (13.1) 103 (12.5)
Deprivation level in area of residence
Low level 1834 1548 (33.0) 286 (34.6)
Medium level 1844 1581 (33.7) 263 (31.8)
High level 1845 1568 (33.4) 277 (34.0)
Clinical factors
Diagnosisa
Schizophrenia (ICD-10: F20) 3706 3103 (66.1) 603 (73.0)
Schizoaffective disorder (ICD-10: F25) 490 386 (8.2) 104 (12.6)
Bipolar affective disorder (ICD-10:F31) 1327 1208 (25.7) 119 (14.4)
Overactive and aggressive behaviour
Not a problem 3081 2625 (56.4) 456 (55.8)
Minor problem 1222 1039 (22.3) 183 (22.4)
Significant problem 1166 987 (21.2) 179 (21.9)
Depressed mood
Not a problem 2769 2335 (50.3) 434 (53.2)
Minor problem 1574 1341 (29.0) 233 (28.6)
Significant problem 1119 970 (20.9) 149 (18.3)
Non-accidental self-injury
Not a problem 4829 4105 (88.3) 724 (88.5)
Minor problem 312 257 (5.5) 55 (6.7)
Significant problem 326 287 (6.2) 39 (4.8)
Physical illness or disability
Not a problem 3715 3177 (68.5) 538 (65.9)
Minor problem 824 689 (14.9) 135 (16.5)
Significant problem 917 774 (16.7) 143 (17.5)
Hallucinations and delusionsa
Not a problem 1824 1609 (34.7) 215 (26.3)
Minor problem 1208 1023 (22.1) 185 (22.7)
Significant problem 2423 2008 (43.3) 415 (51.0)
Problems with activities of daily living
Not a problem 2791 2405 (52.1) 386 (47.7)
Minor problem 1376 1150 (24.9) 226 (27.9)
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associated with future hospital readmissions; rather, readmis-
sion was associated with patients being insufficiently stable at
the point of initial discharge. Greater clinical severity in pa-
tients prescribed APP is one possible mechanism proposed to
explain the higher level of readmission, and is consistent with
the associations we found for APP at discharge with schizo-
phrenia diagnosis, positive symptoms and higher service con-
tact (Kadra et al. 2016; Correll and Gallego 2012). However,
the association with readmission persisted and was largely
unaltered after adjusting for these factors. Adjusting for other
factors known to affect levels of readmission such as possible
medication non-adherence (Haddad et al. 2014) as indicated
by previous CTOs and LAI prescription, and substance use
(Boaz et al. 2013), also made little difference to the results.
Furthermore, the association between polypharmacy and re-
admission was sustained after restricting the analysis to
Table 1 (continued)
Variables Total sample n Antipsychotic
monotherapy n (%)
Antipsychotic
polypharmacy n (%)
Significant problem 1256 1059 (23.0) 197 (24.4)
Problems with living conditions
Not a problem 3069 2559 (57.6) 470 (59.7)
Minor problem 1126 974 (21.6) 152 (19.3)
Significant problem 1106 941 (20.8) 165 (21.0)
Problems with occupation
Not a problem 2179 1865 (41.3) 314 (39.8)
Minor problem 1542 1302 (28.9) 240 (30.4)
Significant problem 1580 1344 (29.8) 236 (29.9)
Problems with relationships
Not a problem 2199 1883 (40.9) 316 (39.1)
Minor problem 1590 1343 (29.1) 247 (30.5)
Significant problem 1628 1382 (30.0) 246 (30.4)
Prior alcohol use (ICD-10:F10)
No 5053 4300 (91.5) 753 (91.2)
Yes 470 397 (8.5) 73 (8.8)
Prior opioid use (ICD-10:F11)
No 5442 4624 (98.4) 818 (99.0)
Yes 81 73 (1.6) 8 (1.0)
Service use
Days of inpatients stay in the previous 6 months (tertiles)a
0–24 days 1777 1573 (34.5) 204 (24.7)
25–65 days 1904 1643 (35.0) 261 (31.6)
66–185 days 1842 1481 (31.5) 361 (43.7)
Days of outpatient contact in the previous 6 months (tertiles)a
1–2 days 1112 979 (28.1) 133 (22.0)
3–8 days 1502 1294 (37.1) 208 (34.4)
9–117 days 1479 1215 (34.8) 264 (43.6)
a There is a statistically significant difference (p < 0.05) between antipsychotic monotherapy and polypharmacy
Table 2 Hospital readmission by antipsychotic regimen
Variables Total N Readmitted n (%) Not readmitted n (%)
Total 5523 1355 (24.5) 4168 (75.5)
Monotherapy 4697 1100 (23.4) 3597 (76.6)
Clozapine monotherapy 395 85 (21.5) 310 (78.5)
Antipsychotic polypharmacy 826 255 (30.9) 571 (69.1)
Clozapine polypharmacy 200 63 (31.5) 137 (68.5)
Psychopharmacology
patients who potentially might have been prescribed antipsy-
chotic monotherapy or polypharmacy based on their propen-
sity scores. We found no evidence to suggest that APP
(whether this was clozapine or non-clozapine) was associated
with a lower risk for readmission, as indicated by Katona et al.
(2014). An important caveat to consider is that despite general
consensus across countries with regard to treatment guidelines
(APA 2010; NICE and NCCMH 2013), it is possible that
clinical practices do differ, and the aforementioned evidence
reflects true differences in prescribing across countries.
The results further indicated that this risk was signifi-
cantly higher for patients prescribed clozapine polypharma-
cy as compared to clozapine monotherapy. The same pattern
was not observed for pat ients on non-clozapine
polypharmacy. Existing research, mainly based on
randomised controlled trials and open-label trials, examining
clozapine polypharmacy has indicated little to no benefit of
this regimen in improving residual clinical symptoms
(Freudenreich and Goff 2002; Taylor et al. 2011), and our
results supported this, by confirming that clozapine
polypharmacy does not appear to reduce the risk for read-
mission for patients with SMI. In addition, our findings
further suggested that within the groups of patients receiv-
ing APP, there could be a sub-population that is at a partic-
ularly high risk for readmission. This could be due to a
number of different factors (such as severity of clinical
symptoms), which need further investigation.
This study had several strengths. SLAM, in common with
other UK secondary mental health services, is a near-
monopoly provider for its geographic catchment (Perera
et al. 2016), increasing the potential generalisability of find-
ings and maximising their reflection of real-world clinical
practice (Stewart et al. 2009). In addition, the large cohort
provided statistical power to detect the primary association
of interest and to adjust for a broad range of potential con-
founders. All exposures were measured on or before the index
discharge, therefore enabling us to make temporal inference
with regards to APP and readmission.
Fig. 1 Kaplan–Meier survival curves displaying the readmission status
of people with serious mental illnesses comparing those discharged on
antipsychotic monotherapy to those discharged on polypharmacy
(n = 5523) (p < 0.001)
Table 3 Multivariable Cox regression analysis of the association between antipsychotic polypharmacy (APP) prescribing and hospital readmission in
individuals with serious mental illness
Regression model Association between APPa and hospital readmission
HR (95% CI) p value
Unadjusted model 1.4 (1.2–1.6) p < 0.001
Model adjusted for sociodemographic and socioeconomic factors 1.4 (1.2–1.6) < 0.001
Model adjusted for clinical symptoms 1.4 (1.3–1.7) p < 0.001
Model adjusted for service use in the previous 6 months 1.3 (1.1–1.6) p < 0.001
Model adjusted for all of the above factors 1.4 (1.2–1.7) p < 0.001
Alternative model adjusted for propensity score as a covariate 1.4 (1.2–1.7) p < 0.001
Sensitivity analyses
Analysis excluding patients on community treatment orders (CTOs)
and previously prescribed long-acting injectables (LAIs)
1.3 (1.1–1.6) p = 0.006
Analysis restricted to patients with schizophrenia diagnosis (ICD 10: F20) 1.5 (1.2–1.8) p < 0.001
Analysis excluding patients from the borough of Lewisham 1.4 (1.2–1.8) p < 0.001
Analysis excluding patients who have obtained their HoNOS score after
the index antipsychotic prescription
1.4 (1.2–1.7) p < 0.001
Analysis restricted to patients who were at risk of being prescribed both
monotherapy and polypharmacy (based on propensity scores)
1.4 (1.2–1.7) p < 0.001
Analysis restricted to patients without clozapine 1.4 (1.1–1.6) p = 0.001
n = 5523 individuals, 1355 readmissions
aMonotherapy is used as the reference group
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There were several potential limitations in this study, which
need to be borne in mind. Despite multiple adjustment, resid-
ual confounding cannot be excluded absolutely in an observa-
tional design. Specifically, we did not capture factors such as
time known to services or duration of prior hospital admis-
sions (Boaz et al. 2013). In addition, we were unable to iden-
tify the concomitant prescription of other non-antipsychotic
drugs, which could have possibly had an effect on readmis-
sion. Furthermore, symptom assessment in this study was lim-
ited to individual HoNOS items, measured at one point in
time. This scale has received some previous criticism with
regards to its measurement of symptoms (Bebbington et al.
1999), and we were only able to analyse a composite measure
of clinical symptoms and daily functioning. Although we
employed propensity score adjustment and restriction, con-
founding by indication cannot be completely ruled out.
Our findings have several important potential implications.
Our results indicated that patients on APP are generally more
unwell; therefore, the prescription of regimens that lack em-
pirical support is likely to further increase patient burden al-
ready present in this population (Ganguly et al. 2004; Paton
et al. 2008). We found that patients receiving clozapine
polypharmacy had a particularly elevated risk for readmission
as compared to clozapine monotherapy. This is suggestive of
potential difference in treatment needs across patients receiv-
ing APP, further indicating that this is not a homogenous pop-
ulation. Therefore, future research would benefit from further
examining this sub-group in relation to their clinical symp-
toms, treatment needs and course of antipsychotic medication
prescribing (i.e. time from non-clozapine monotherapy to clo-
zapine augmentation). Lastly, the findings provide further sup-
port for the need to reduce APP prescribing. APP prescribing
has remained widespread not only across clinical services but
also across countries and time (Gallego et al. 2012), with a
trend that has been resistant to change (Paton et al. 2008) and
with a high cost to service. More specifically, APP has been
associated with a higher bed occupancy and length of
inpatient stay, in addition to extra cost associatedwith multiple
medication prescribing (Baandrup et al. 2012; Gilmer et al.
2007). Evidence from a recent quality improvement pro-
gramme has indicated that polypharmacy can be reduced suc-
cessfully (Mace and Taylor 2015). Therefore, there is a clear
need for similar programmes to be implemented on a wider
national level.
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creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
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Creative Commons license, and indicate if changes were made.
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